"Molecular Basis, Challenges, and Strategies of CD7 as a Target for Immunotherapy in T-Cell Malignancies"

Author: Senior Product Manager of UA Views：104

This article systematically elaborates on the molecular structural characteristics of CD7 as a member of the immunoglobulin superfamily and its expression patterns in T-cell and NK-cell lineages. It analyzes the coreceptor mechanisms by which CD7 mediates T-cell activation and NK-cell functional regulation, and explores the high-expression features of CD7 in hematologic malignancies such as T-cell acute lymphoblastic leukemia, acute myeloid leukemia, and NK/T-cell lymphoma, as well as its clinical translational value as a target for CAR-T therapy.

Recent Advances
Product Information

Recent Advances

Molecular Basis, Challenges, and Strategies of CD7 as an Immunotherapeutic Target for T-Cell Malignancies

Summary: This article systematically elaborates on the molecular structural characteristics of CD7 as a member of the immunoglobulin superfamily and its expression patterns in T-cell and NK-cell lineages. It analyzes its coreceptor mechanisms in mediating T-cell activation and NK-cell functional regulation, explores its high expression features in hematologic malignancies such as T-cell acute lymphoblastic leukemia, acute myeloid leukemia, and NK/T-cell lymphoma, and discusses its clinical translational value as a CAR-T therapy target. The article also deeply examines core challenges faced by CD7 CAR-T therapy, including "fratricide" and graft-versus-host disease, and introduces strategies such as gene editing and protein expression blockade to overcome these challenges. Additionally, it highlights the application of fluorescently labeled recombinant proteins in related research and detection.

1. Molecular Structure and Genetic Localization of CD7.

CD7, also known as GP40, TP41, or LEU-9, is a single-chain transmembrane glycoprotein with a molecular weight of approximately 40 kDa, composed of 240 amino acid residues and belonging to the immunoglobulin superfamily. The CD7 gene is located on human chromosome 17, with a total DNA sequence length of about 3.0 kb. The mature mRNA transcribed from this gene contains four functionally distinct exons: sequences encoding the immunoglobulin-like domain, sequences encoding the fusion region, sequences encoding the transmembrane domain, and sequences encoding the cytoplasmic tail. These four exons correspond to different functional modules of the CD7 molecule, collectively participating in and finely regulating the growth and differentiation processes of T-cells at various developmental stages.

2. Expression Patterns of CD7 in Immune Cell Lineages.

CD7 is typically expressed on approximately 85% of peripheral blood T-cells and natural killer (NK) cells and their precursor cells, making it widely regarded as one of the key markers for T-cell and NK-cell lineages. In addition to mature T-cell subsets, CD7 is also expressed at low levels on the surface of some myeloid cells and exhibits abnormally high expression in various hematologic malignancy cells. Notably, there exists a population of CD7-negative normal T-cells that show no significant defects in T-cell development, maturation, or immune defense functions. This observation suggests that while CD7 is a hallmark molecule of the T-cell lineage, its absence does not substantially impact the basic functions of T-cells, thereby providing an important safety foundation for CD7-targeted immunotherapy—even if CD7-positive cells are eliminated during treatment, the CD7-negative T-cell population can still maintain fundamental immune defense capabilities.

3. Biological Functions and Signal Transduction Mechanisms of CD7.

CD7 is a costimulatory receptor protein that assists in T-cell activation and interactions with other subsets of immune cells. In T-cells, CD7 synergizes with T-cell receptor signals to lower the antigen threshold for T-cell activation, promoting T-cell proliferation and effector function differentiation. In NK cells, CD7 mediates transmembrane calcium ion flow. When specific signaling molecules bind to CD7, they can stimulate NK cells to secrete interferon-gamma (IFN-γ) while enhancing NK-cell cytotoxic activity and adhesion to fibronectin, thereby promoting NK-cell recruitment to inflammatory sites and the exertion of effector functions.

4. High Expression of CD7 in Hematologic Malignancies and Its Clinical Significance.

CD7 is one of the important markers on the surface of tumor cells in hematologic malignancies and is highly expressed in many aggressive blood cancers. In acute T-cell lymphoblastic leukemia (T-ALL), over 95% of lymphoblastic leukemia and lymphoma cases express CD7, and some peripheral T-cell lymphomas are also CD7-positive. T-ALL is a highly aggressive hematologic T-cell malignancy, accounting for approximately 25% of adult ALL cases and 15% of pediatric ALL cases. T-ALL leads to abnormal proliferation of immature T-cells and significantly elevated CD7 expression levels, providing a theoretical basis for CD7 CAR-T therapy. In acute myeloid leukemia (AML), abnormal upregulation of CD7 expression is one of the poor prognostic indicators and is often accompanied by myelodysplasia, decreased MPO expression levels, and frequent PDGFRA-ETV6 gene fusion. In NK/T-cell lymphoma, early-stage NK cells and T-cells often exhibit overexpression of early T-cell lineage surface markers such as CD2, CD3, CD5, and CD7. Given that CD7 has no significant impact on peripheral blood T-cell function and the CD7-negative T-cell population can maintain basic immune functions, CD7 has been identified as an ideal target for CAR-T or antibody-drug conjugate strategies.

5. Core Challenges of CD7 CAR-T Therapy.

Although CD7-targeted therapy has clear theoretical advantages, it faces unique obstacles in clinical translation. The first core challenge stems from the "pan-T-cell" expression feature of CD7—since CD7 is expressed on most T-cells and NK cells, CD7 CAR-T cells recognize and attack each other during preparation and expansion, leading to severe "fratricide." The direct consequence is a significant reduction in CAR-T cell numbers by the fifth day of in vitro culture, severely limiting the production and infusion dose of therapeutic CAR-T cells. The second core challenge involves the source of CAR-T cells. In autologous CAR-T preparation, sufficient normal autologous T-cells must be isolated and expanded from the patient's blood or bone marrow cells. However, the peripheral blood of T-cell malignancy patients is often filled with malignant T-cells, making it technically difficult to obtain enough healthy autologous T-cells, and the preparation process is costly. The third core challenge is the risk of graft-versus-host disease (GVHD). If healthy donor T-cells are used to produce universal CAR-T, the infused donor-derived T-cells may attack the patient's normal tissues, causing severe GVHD and potentially fatal complications.

6. Key Strategies to Overcome Challenges: CD7 Expression Blockade.

To address the "fratricide" dilemma of CAR-T cells, researchers have developed two main strategies to block CD7 expression in CAR-T cells. The first strategy involves using gene editing technology to knock out the CD7 gene, permanently eliminating CD7 surface expression on CAR-T cells. The second strategy employs endoplasmic reticulum (ER) anchoring by fusing the CD7-binding domain with an ER retention signal, trapping newly synthesized CD7 protein in the ER and preventing its normal transport to the cell surface, thereby achieving functional CD7 protein expression blockade. CAR-T cells prepared using these methods, which do not express CD7, not only retain their expansion capacity and CAR-mediated cytotoxic effects but also largely avoid "fratricide" among CAR-T cells. Simultaneously, CD7-negative CAR-T cells exhibit potent and specific cytotoxic effects against CD7-positive hematologic malignancies, removing a key obstacle for clinical application. According to incomplete statistics, 12 CD7 CAR-T products have entered clinical trials globally, with three in Phase II trials developed by the First Affiliated Hospital of Soochow University, Beijing Borui Hospital, and Shanghai Yake/Zhejiang University, respectively. PersonGen BioTech also has three CAR-T products and one CD7 CAR-NK in clinical development, while Gracell Biotechnologies' GC-027 and GC-502 are advancing steadily.

7. Conclusion.

CD7, with its hallmark expression in T-cell and NK-cell lineages, high coverage in T-ALL, AML, and NK/T-cell lymphoma, and the safety window provided by CD7-negative T-cells maintaining basic immune functions, has become a highly promising target in the field of immunotherapy for T-cell malignancies. U-Antibody offers FITC-Labeled CD7 Fc Chimera Protein, Human, which, with its precise molecular design, Fc tag-induced dimerization advantages, and the high brightness and stability of FITC dye, provides a reliable detection tool for CD7-related CAR-T cell screening, targeted drug binding activity analysis, and basic research.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next